POTENTIATE trial ongoing in patients with oncogene amplified cancers, with initial proof of concept data expected in the second ...

Boundless Bio Inc. ( ($BOLD) ) has released its Q4 earnings. Here is a breakdown of the information Boundless Bio Inc. presented to its investors.

With a $152 million cash position at the end of 2024, Boundless projects operating runway into 2027. “We made important strides in 2024 as we ...

The trial’s first phase will begin in university hospitals across the Netherlands, Denmark, Germany and Sweden.

Oncogene permanent activation in a single targeted cell of zebrafish together with a reprogramming factor transient activation is sufficient to induce the malignant transformation of the cell and ...

Notch can function as an oncogene. Aberrant expression of the dominant active cytoplasmic domain of Notch receptors in haematopoietic cells because of chromosomal translocation or viral ...

Our laboratory studies oncogene and tumor suppressor induced cancer-specific cellular programs, which cause therapeutic vulnerabilities in breast cancer. Our current research specifically focuses on ...

Neuroblastoma, an aggressive malignancy originating from neural crest cells, accounts for 15% of cancer-related deaths in children. Treatment strategies include systemic chemotherapy, radiation or ...